Approximately 4,500 medicines were in the preclinical development phase of the drug pipeline in the United States, as of April 2020. Around 560 were being developed to treat pediatric diseases.
What is the preclinical phase of drug development?
Once a promising compound has been discovered, further experiments must take place to test all of its potential benefits and side effects. The preclinical stage sees further testing of the compound in laboratories to discover how the drug works and whether it is likely to be safe in humans. Globally, there were more than 9,600 medicines in the preclinical development stage in 2020. Researchers use preclinical testing to decide whether the drug should continue to clinical trials, where it will be tested in humans.
The journey of a drug from laboratory to pharmacy
The number of drugs in the overall research and development pipeline exceeded 17,700 in 2020. The process starts with basic research and ends with final approval and monitoring from the U.S. Food and Drug Administration (FDA) – for cancer drugs, it can take up to 15 years to complete this journey. In 2019, member companies of the trade group PhRMA (Pharmaceutical Research and Manufacturers of America) invested close to 83 billion U.S. dollars worldwide in research and development.
Number of biopharma medicines in development in the U.S. as of April 2020, by select therapeutic category*
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Statista Accounts:
Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.
PhRMA. (December 15, 2020). Number of biopharma medicines in development in the U.S. as of April 2020, by select therapeutic category* [Graph]. In Statista. Retrieved May 19, 2022, from https://www.statista.com/statistics/258152/biologic-medicines-in-development-by-therapeutic-category-2016/
PhRMA. "Number of biopharma medicines in development in the U.S. as of April 2020, by select therapeutic category*." Chart. December 15, 2020. Statista. Accessed May 19, 2022. https://www.statista.com/statistics/258152/biologic-medicines-in-development-by-therapeutic-category-2016/
PhRMA. (2020). Number of biopharma medicines in development in the U.S. as of April 2020, by select therapeutic category*. Statista. Statista Inc.. Accessed: May 19, 2022. https://www.statista.com/statistics/258152/biologic-medicines-in-development-by-therapeutic-category-2016/
PhRMA. "Number of Biopharma Medicines in Development in The U.S. as of April 2020, by Select Therapeutic Category*." Statista, Statista Inc., 15 Dec 2020, https://www.statista.com/statistics/258152/biologic-medicines-in-development-by-therapeutic-category-2016/
PhRMA, Number of biopharma medicines in development in the U.S. as of April 2020, by select therapeutic category* Statista, https://www.statista.com/statistics/258152/biologic-medicines-in-development-by-therapeutic-category-2016/ (last visited May 19, 2022)
